Statistics, Modelling and Economics Department, UK Health Security Agency, London, UK.
Clinical and Protecting Health, Public Health Scotland, Glasgow, UK.
Influenza Other Respir Viruses. 2024 May;18(5):e13284. doi: 10.1111/irv.13284.
We report 2023/2024 season interim influenza vaccine effectiveness for three studies, namely, primary care in Great Britain, hospital settings in Scotland and hospital settings in England.
A test negative design was used to estimate vaccine effectiveness.
Estimated vaccine effectiveness against all influenzas ranged from 63% (95% confidence interval 46 to 75%) to 65% (41 to 79%) among children aged 2-17, from 36% (20 to 49%) to 55% (43 to 65%) among adults 18-64 and from 40% (29 to 50%) to 55% (32 to 70%) among adults aged 65 and over.
During a period of co-circulation of influenza A(H1N1)pdm09 and A(H3N2) in the United Kingdom, evidence for effectiveness of the influenza vaccine in both children and adults was found.
我们报告了三个研究的 2023/2024 季节流感疫苗有效性，分别是英国的初级保健、苏格兰的医院环境和英格兰的医院环境。
采用阴性测试设计来估计疫苗的有效性。
在年龄为 2-17 岁的儿童中，针对所有流感的估计疫苗有效性范围为 63%（95%置信区间为 46%至 75%）至 65%（41%至 79%）；在 18-64 岁的成年人中，针对所有流感的估计疫苗有效性范围为 36%（20%至 49%）至 55%（43%至 65%）；在年龄为 65 岁及以上的成年人中，针对所有流感的估计疫苗有效性范围为 40%（29%至 50%）至 55%（32%至 70%）。
在英国甲型流感 H1N1pdm09 和甲型流感 H3N2 共同流行期间，发现了流感疫苗在儿童和成人中的有效性证据。
